77907EB2-E529-4633-A580-C6DD7993A704
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.22996057818659657
- age_years
- 55
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.519
- MYC_TARGETS_V2+0.502
- INTERFERON_GAMMA_RESPONSE+0.459
- DNA_REPAIR+0.448
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.411
- E2F_TARGETS+0.406
- MYC_TARGETS_V1+0.401
- OXIDATIVE_PHOSPHORYLATION+0.390
- ALLOGRAFT_REJECTION+0.384
- COAGULATION+0.310
Top 10 suppressed
- UV_RESPONSE_DN-0.382
- HEDGEHOG_SIGNALING-0.359
- PROTEIN_SECRETION-0.247
- SPERMATOGENESIS-0.240
- ANDROGEN_RESPONSE-0.235
- ESTROGEN_RESPONSE_EARLY-0.167
- KRAS_SIGNALING_DN-0.144
- MITOTIC_SPINDLE-0.132
- TGF_BETA_SIGNALING-0.103
- WNT_BETA_CATENIN_SIGNALING-0.066
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E00A399D-E6C3-439D-8E70-A7AD5DF5F5E2 | — | — | 0.887 |
| 2 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.886 |
| 3 | A239061B-989B-4F2F-BAAC-13BADFDBAC11 | — | — | 0.885 |
| 4 | 56BBED6E-8ADB-430B-A85C-D3773F929447 | — | — | 0.883 |
| 5 | 4F09B010-97EC-4792-BF5A-42E9EF55894D | — | — | 0.876 |
| 6 | 46C5EF69-5EAF-4FBA-BE47-28A8E7F3D9A2 | — | — | 0.874 |
| 7 | 31550B35-DA39-4294-8368-811A412B2E3A | — | — | 0.873 |
| 8 | 060C8F0B-DAB8-43DB-80C9-3404AFCC0B7D | — | — | 0.865 |
| 9 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.862 |
| 10 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.519 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.502 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.459 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.448 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.411 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.406 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.401 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.384 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.306 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.297 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.255 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.254 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.225 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.223 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.216 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.214 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.211 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.206 | Inavolisib | — uncovered |